Analysis Date: 2026-02-23
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

ImmunityBio, Inc. is currently trading at $9.64 (🟢 +10.86% today) with a market capitalization of $9.50B.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV.

Price & Valuation

Current Price: $9.64 (at 1:36 PM ET)
Current Volume: 71.6M (avg 30.2M)
Day Range: $9.62 - $11.00
52-Week Range: $1.83 - $11.00
P/E Ratio: N/A

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-02-23.

Market Context

Healthcare Sector: 0.21158% | Sector P/E: 35.78

Major Indices:

• S&P 500: $6854.96 (🔴 -0.79%)
• NASDAQ Composite: $22690.92 (🔴 -0.85%)
• Dow Jones Industrial Average: $49004.49 (🔴 -1.25%)

Peer Comparison

Peer comparison (11 companies):

• IBRX - ImmunityBio, Inc. ($9.64, +10.9%) ← Current
• COGT - Cogent Biosciences, Inc. ($36.73, -1.6%)
• DNLI - Denali Therapeutics Inc. ($20.59, +2.0%)
• BEAM - Beam Therapeutics Inc. ($28.18, +2.1%)
• LQDA - Liquidia Corporation ($32.43, -3.5%)
• VRDN - Viridian Therapeutics, Inc. ($28.31, +3.2%)
• GLPG - Galapagos N.V. ($33.59, -0.5%)
• ETNB - 89bio, Inc. ($14.84, 0.0%)
• RCUS - Arcus Biosciences, Inc. ($18.75, -1.2%)
• AGIO - Agios Pharmaceuticals, Inc. ($30.20, +3.2%)
• RXRX - Recursion Pharmaceuticals, Inc. ($3.41, -0.3%)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $38.28M
• Net Income: $-61.94M
• EPS: $-0.06
• Revenue Growth (QoQ): +19.4%

Earnings Calendar

Next Earnings Report: 2026-05-11 (Before Market Open)

2 upcoming earnings dates tracked

Most Recent Report: 2025-11-04

• EPS: $-0.07 (Est: $-0.10) ✓ Beat
• Revenue: $0.03B

Historical Data: 45 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $7.00 (-27.4% upside)
• Range: $7.00 - $7.00
• Median: $7.00

Next Quarter Estimates (2028-12-30):

• Revenue: $352.10M
• EPS: $0.14

Analyst Consensus

Overall Rating: Buy

Rating Distribution (56 total ratings):

• 🟢 Buy/Outperform: 51 (91.1%)
• ⚪ Hold/Neutral: 5 (8.9%)
• 🔴 Sell/Underperform: 0 (0.0%)

Recent Analyst Actions:

• D. Boral Capital (2026-02-19): Maintained Buy
• D. Boral Capital (2026-02-17): Maintained Buy
• HC Wainwright & Co. (2026-01-26): Maintained Buy
• D. Boral Capital (2026-01-23): Maintained Buy
• BTIG (2026-01-23): Maintained Buy

Consensus based on 56 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 2 trading signal(s) in the last 60 days:

• 2026-02-19: Momentum Swing - breakout @ $8.61
• 2026-01-09: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $2.33

Insider Activity

Recent Transactions (Last 10):

• Buys: 4
• Sells: 6

Notable Transactions:

• 2026-02-10: SOON-SHIONG PATRICK - Buy (Option Exercise, 274,122 shares)
• 2026-02-10: SOON-SHIONG PATRICK - Sell (Tax Withholding, 118,560 shares @ $6.93)
• 2026-02-10: SOON-SHIONG PATRICK - Sell (Option Exercise, 274,122 shares)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

House of Representatives: 1 transactions tracked

Recent Activity:

• 🔴 Daniel Goldman (NY10): Sale on 2023-03-06 @ $1.76, Amount: $1,001 - $15,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

ImmunityBio's stock has soared on 700% year-over-year revenue growth in 2025, EU approval for Anktiva in bladder cancer, and new global partnerships expanding access to 33 countries. Positive clinical updates and beats on revenue estimates dominate recent coverage, despite ongoing investor investigations. Overall sentiment is strongly bullish amid robust commercial progress.

Key Themes:

• Revenue Growth
• Regulatory Approvals
• Global Expansion

Sentiment: Positive (92% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Bullish 📈 (Score: 0.305)

Post Analysis:

• Total posts: 22
• Bullish: 16 (72.7%)
• Bearish: 6 (27.3%)
• Neutral: 0 (0.0%)
• Total engagement: 532 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering IBRX:

• Why ImmunityBio Stock Is Soaring Again Today (fool.com, 2026-02-23) — Read more
• ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth (benzinga.com, 2026-02-23) — Read more
• ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (zacks.com, 2026-02-23) — Read more
• Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More (seekingalpha.com, 2026-02-23) — Read more
• ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally (businesswire.com, 2026-02-23) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-02-23 10:37:05 AM PST

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.